Drugs Made In America Acquisition (DMAAR) Non-Current Deffered Revenue (2025)
Drugs Made In America Acquisition (DMAAR) posted Non-Current Deffered Revenue of $6.9 million for Q4 2025, little changed on a QoQ basis from $6.9 million in Q3 2025.
Drugs Made In America Acquisition (DMAAR) Non-Current Deffered Revenue (2025) Analysis & Trends
Drugs Made In America Acquisition's Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $6.9 million for Q4 2025.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.9 million (changed N/A YoY) and the FY2025 annual result came in at $6.9 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $6.9 million for Q4 2025 at Drugs Made In America Acquisition, roughly flat from $6.9 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $6.9 million in Q1 2025 and bottomed at $6.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | SIM Acquisition Corp. I | 314.52 Mn | 314.52 Mn | - | - |
| 2 | Thayer Ventures Acquisition | 208.29 Mn | 208.29 Mn | - | 7.57 Mn |
| 3 | Newbury Street II Acquisition | 185.26 Mn | 185.26 Mn | - | 6.04 Mn |
| 4 | Dynamix | 178.78 Mn | 178.78 Mn | - | 6.64 Mn |
| 5 | Hallmark Venture | 103.01 Mn | 102.76 Mn | - | - |
| 6 | Voyager Acquisition | 99.58 Mn | 99.45 Mn | - | 12.05 Mn |
| 7 | Gores Holdings X | 95.80 Mn | 95.37 Mn | - | 10.76 Mn |
| 8 | Archimedes Tech SPAC Partners | 89.88 Mn | 89.88 Mn | - | - |
| 9 | Cohen Circle Acquisition | 80.05 Mn | 80.05 Mn | - | 10.78 Mn |
| 10 | Drugs Made In America Acquisition | 1.46 Mn | 1.46 Mn | - | 6.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.90 Mn |
| Sep 30, 2025 | 6.90 Mn |
| Jun 30, 2025 | 6.90 Mn |
| Mar 31, 2025 | 6.90 Mn |